Activation of PPARα lowers synthesis and concentration of cholesterol by reduction of nuclear SREBP-2

Biochemical Pharmacology

Volumn 73, Issue 4, 2007, Pages 574-585

  König, Bettina ^a   Koch, Alexander ^a   Spielmann, Julia ^a   Hilgenfeld, Christian ^a   Stangl, Gabriele I ^a   Eder, Klaus ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Cholesterol; HMG CoA reductase; Insulin induced gene (Insig); LDL receptor; Peroxisome proliferator activated receptor (PPAR) ; Sterol regulatory element binding protein (SREBP) 2

Indexed keywords

CLOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE (NADPH); LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; PROTEIN; PROTEIN INSIG 1; PROTEIN INSIG 2; PROTEIN PRECURSOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ACYL COENZYME A OXIDASE; CHOLESTEROL; CYP4A22 PROTEIN, RAT; CYTOCHROME P450; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOCHOLESTEROLEMIC AGENT; INSIG1 PROTEIN, RAT; MEMBRANE PROTEIN; PYRIMIDINE DERIVATIVE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE TARGETING; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; RAT; RECEPTOR GENE; ANIMAL; BIOSYNTHESIS; DRUG POTENTIATION; GENETICS; LIVER; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE; WESTERN BLOTTING;

ACYL-COA OXIDASE; ANIMALS; ANTICHOLESTEREMIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL NUCLEUS; CHOLESTEROL; CHOLESTEROL, VLDL; CLOFIBRATE; CYTOCHROME P-450 ENZYME SYSTEM; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LIVER; MALE; MEMBRANE PROTEINS; PPAR ALPHA; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LDL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIGLYCERIDES;

EID: 33845955966     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.10.027     Document Type: Article

References (65)

1. Brown M.S., and Goldstein J.L. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci USA 96 (1999) 11041-11048
2. Horton J.D., Goldstein J.L., and Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109 (2002) 1125-1131
3. Shimomura I., Shimano H., Horton J.D., Goldstein J.L., and Brown M.S. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 99 (1997) 838-845
4. Espenshade P.J., Li W.P., and Yabe D. Sterols block binding of COPII proteins to SCAP, thereby controlling SCAP sorting in ER. Proc Natl Acad Sci USA 99 (2002) 11694-11699
5. Goldstein J.L., Rawson R.B., and Brown M.S. Mutant mammalian cells as tools to delineate the sterol regulatory element-binding protein pathway for feedback regulation of lipid synthesis. Arch Biochem Biophys 397 (2002) 139-148
6. Yang T., Espenshade P.J., Wright M.E., Yabe D., Gong Y., Aebersold R., et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 110 (2002) 489-500
7. Yabe D., Brown M.S., and Goldstein J.L. Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc Natl Acad Sci USA 99 (2002) 12753-12758
8. Yabe D., Komuro R., Liang G., Goldstein J.L., and Brown M.S. Liver-specific mRNA for Insig-2 down-regulated by insulin: implications for fatty acid synthesis. Proc Natl Acad Sci USA 100 (2003) 3155-3160
9. Kast-Woelbern H.R., Dana S.L., Cesario R.M., Sun L., de Grandpre L.Y., Brooks M.E., et al. Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis. J Biol Chem 279 (2004) 23908-23915
10. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20 (1999) 649-688
11. Duval C., Chinetti G., Trottein F., Fruchart J.C., and Staels B. The role of PPARs in atherosclerosis. Trends Mol Med 8 (2002) 422-430
12. Chinetti G., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49 (2000) 497-505
13. Schoonjans K., Martin G., Staels B., and Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 8 (1997) 159-166
14. Mandard S., Müller M., and Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61 (2004) 393-416
15. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
16. Kris-Etherton P.M., and Yu S. Individual fatty acid effects on plasma lipids and lipoproteins: human studies. Am J Clin Nutr 65 (1997) 1628S-1644S
17. Eder K., Suelzle A., Skufca P., Brandsch C., and Hirche F. Effects of dietary thermoxidized fats on expression and activities of hepatic lipogenic enzymes in rats. Lipids 38 (2003) 31-38
18. Sirtori M., Montanari G., Gianfranceschi G., Malacrida M.G., Battistin P., Morazzoni G., et al. Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis. Atherosclerosis 49 (1983) 149-161
19. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 18 (2002) 269-276
20. Peters J.M., Hennuyer N., Staels B., Fruchart J.C., Fievet C., Gonzalez F.J., et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 272 (1997) 27307-27312
21. Patel D.D., Knight B.L., Wiggins D., Humphreys S.M., and Gibbons G.F. Disturbances in the normal regulation of SREBP-sensitive genes in PPAR alpha-deficient mice. J Lipid Res 42 (2001) 328-337
22. Hashimoto F., Taira S., and Hayashi H. Changes in isoprenoid lipid synthesis by gemfibrozil and clofibrate in rat hepatocytes. Biochem Pharmacol 59 (2000) 1203-1210
23. Roglans N., Peris C., Verd J.C., Alegret M., Vazquez M., Sanchez R.M., et al. Increase in hepatic expression of SREBP-2 by gemfibrozil administration to rats. Biochem Pharmacol 62 (2001) 803-809
24. Shiota Y., Ikeda M., Hashimoto F., and Hayashi H. Effects of peroxisome proliferators gemfibrozil and clofibrate on syntheses of dolichol and cholesterol in rat liver. J Biochem (Tokyo) 134 (2003) 197-202
25. Poirier H., Braissant O., Niot I., Wahli W., and Besnard P. 9-cis-Retinoic acid enhances fatty acid-induced expression of the liver fatty acid-binding protein gene. FEBS Lett 412 (1997) 480-484
26. Vanden Heuvel J.P., Kreder D., Belda B., Hannon D.B., Nugent C.A., Burns K.A., et al. Comprehensive analysis of gene expression in rat and human hepatoma cells exposed to the peroxisome proliferator WY14,1643. Toxicol Appl Pharmacol 188 (2003) 185-198
27. Landrier J.F., Thomas C., Grober J., Duez H., Percevault F., Souidi M., et al. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent. J Biol Chem 279 (2004) 45512-45518
28. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M.G., et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11 (1997) 779-791
29. Grau R., Punzon C., Fresno M., and Iniguez M.A. Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. Biochem J 395 (2006) 81-88
30. Rodriguez C., Cabrero A., Roglans N., Adzet T., Sanchez R.M., Vazquez M., et al. Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells. Biochem Pharmacol 61 (2001) 357-364
31. König B., and Eder K. Differential action of 13-HPODE on PPARα downstream genes in rat Fao and human HepG2 hepatoma cell lines. J Nutr Biochem 17 (2006) 410-418
32. Yu-Poth S., Yin D., Kris-Etherton P.M., Zhao G., and Etherton T.D. Long-chain polyunsaturated fatty acids upregulate LDL receptor protein expression in fibroblasts and HepG2 cells. J Nutr 135 (2005) 2541-2545
33. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
34. Horton J.D., Bashmakov Y., Shimomura I., and Shimano H. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci USA 95 (1998) 5987-5992
35. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) e29-e45
36. Woo C.W.H., Siow Y.L., Pierce G.N., Choy P.C., Minuk G.Y., Mymin D., et al. Hyperhomocysteinemia induces hepatic cholesterol biosynthesis and lipid accumulation via activation of transcription factors. Am J Physiol Endocrinol Metab 288 (2005) E1002-E1010
37. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
38. Hara A., and Radin N.S. Lipid extraction of tissues with a low-toxicity solvent. Anal Biochem 90 (1978) 420-426
39. De Hoff J.L., Davidson J.H., and Kritchevsky V. An enzymatic assay for determining free and total cholesterol in tissues. Clin Chem 24 (1978) 433-435
40. Mehran M., Seidman E., Marchand R., Gurbindo C., and Levy E. Tumor necrosis factor-alpha inhibits lipid and lipoprotein transport by Caco-2 cells. Am J Physiol 269 (1995) G953-G960
41. Lovati M.R., Manzoni C., Gianazza E., Arnoldi A., Kurowska E., Carroll K., et al. Soy protein peptides regulate cholesterol homeostasis in Hep G2 cells. J Nutr 130 (2000) 2543-2549
42. Levy E., Thibault L., and Menard D. Intestinal lipids and lipoproteins in the human fetus: modulation by epidermal growth factor. J Lipid Res 33 (1992) 1607-1617
43. McPherson R., and Gauthier A. Molecular regulation of SREBP function: the Insig-SCAP connection and isoform-specific modulation of lipid synthesis. Biochem Cell Biol 82 (2004) 201-211
44. Hawkins J.M., Jones W.E., Bonner F.W., and Gibson G.G. The effect of peroxisome proliferators on microsomal, peroxisomal, and mitochondrial enzyme activities in the liver and kidney. Drug Metab Rev 18 (1987) 441-515
45. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15 (1995) 3012-3022
46. Bentley P., Calder I., Elcombe C., Grasso P., Stringer D., and Wiegand H.J. Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol 31 (1993) 857-907
47. Aldridge T.C., Tugwood J.D., and Green S. Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription. Biochem J 306 (1995) 473-479
48. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94 (1997) 4312-4317
49. Amemiya-Kudo M., Shimano H., Hasty A.H., Yahagi N., Yoshikawa T., Matsuzaka T., et al. Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes. J Lipid Res 43 (2002) 1220-1235
50. Engelking L.J., Kuriyama H., Hammer R.E., Horton J.D., Brown M.S., Goldstein J.L., et al. Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J Clin Invest 113 (2004) 1168-1175
51. Adams C.M., Reitz J., De Brabander J.K., Feramisco J.D., Li L., Brown M.S., et al. Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and Insigs. J Biol Chem 279 (2004) 52772-52780
52. Sever N., Song B.L., Yabe D., Goldstein J.L., Brown M.S., and DeBose-Boyd R.A. Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol. J Biol Chem 278 (2003) 52479-52490
53. Lee P.C., Sever N., and Debose-Boyd R.A. Isolation of sterol-resistant Chinese hamster ovary cells with genetic deficiencies in both Insig-1 and Insig-2. J Biol Chem 280 (2005) 25242-25249
54. Guerre-Millo M., Gervois P., Raspe E., Madsen L., Poulain P., Derudas B., et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275 (2000) 16638-16642
55. Ye J.M., Doyle P.J., Iglesias M.A., Watson D.G., Cooney G.J., and Kraegen E.W. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 50 (2001) 411-417
56. Chou C.J., Haluzik M., Gregory C., Dietz K.R., Vinson C., Gavrilova O., et al. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem 277 (2002) 24484-24489
57. Frederiksen K.S., Wulf E.M., Wassermann K., Sauerberg P., and Fleckner J. Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists. J Mol Endocrinol 30 (2003) 317-329
58. Berndt J., Gaumert R., and Still J. Mode of action of the lipid-lowering agents, clofibrate and BM 15075, on cholesterol biosynthesis in rat liver. Atherosclerosis 30 (1978) 147-152
59. Hashimoto F., Taira S., and Hayashi H. Comparison of the effects of gemfibrozil and clofibrate on peroxisomal enzymes and cholesterol synthesis of rat hepatocytes. Biol Pharm Bull 21 (1998) 1142-1147
60. Hayashi H., and Takahata S. Role of peroxisomal fatty acyl-CoA beta-oxidation in phospholipid biosynthesis. Arch Biochem Biophys 284 (1991) 326-331
61. Le Jossic-Corcos C., Duclos S., Ramirez L.C., Zaghini I., Chevillard G., Martin P., et al. Effects of peroxisome proliferator-activated receptor alpha activation on pathways contributing to cholesterol homeostasis in rat hepatocytes. Biochim Biophys Acta 1683 (2004) 49-58
62. Knight B.L., Hebbachi A., Hauton D., Brown A.M., Wiggins D., Patel D.D., et al. A role for PPARalpha in the control of SREBP activity and lipid synthesis in the liver. Biochem J 389 (2005) 413-421
63. Panda T., and Devi V.A. Regulation and degradation of HMGCo-A reductase. Appl Microbiol Biotechnol 66 (2004) 143-152
64. Sever N., Yang T., Brown M.S., Goldstein J.L., and DeBose-Boyd R.A. Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain. Mol Cell 11 (2003) 25-33
65. Nicolosi R.J., Rogers E.J., Kritchevsky D., Scimeca J.A., and Huth P.J. Dietary conjugated linoleic acid reduces plasma lipoproteins and early aortic atherosclerosis in hypercholesterolemic hamsters. Artery 22 (1997) 266-277